Compare CBZ & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBZ | TYRA |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | CBZ | TYRA |
|---|---|---|
| Price | $42.14 | $31.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $41.33 | ★ $47.50 |
| AVG Volume (30 Days) | 827.4K | ★ 923.4K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $922,003,000.00 | N/A |
| Revenue This Year | $3.92 | N/A |
| Revenue Next Year | $4.12 | N/A |
| P/E Ratio | $23.10 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $24.29 | $9.96 |
| 52 Week High | $77.91 | $40.65 |
| Indicator | CBZ | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 71.70 | 49.81 |
| Support Level | $27.84 | $28.92 |
| Resistance Level | $54.00 | $31.57 |
| Average True Range (ATR) | 1.91 | 1.87 |
| MACD | 0.71 | 0.05 |
| Stochastic Oscillator | 82.83 | 47.47 |
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.